236 related articles for article (PubMed ID: 19878137)
1. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.
Warburton W; Hertzman C; Oberlander TF
Acta Psychiatr Scand; 2010 Jun; 121(6):471-9. PubMed ID: 19878137
[TBL] [Abstract][Full Text] [Related]
2. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.
Oberlander TF; Warburton W; Misri S; Aghajanian J; Hertzman C
Arch Gen Psychiatry; 2006 Aug; 63(8):898-906. PubMed ID: 16894066
[TBL] [Abstract][Full Text] [Related]
3. Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors.
Pawluski JL; Galea LA; Brain U; Papsdorf M; Oberlander TF
Pediatrics; 2009 Oct; 124(4):e662-70. PubMed ID: 19786426
[TBL] [Abstract][Full Text] [Related]
4. Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data.
Singal D; Brownell M; Chateau D; Ruth C; Katz LY
BMJ Open; 2016 Nov; 6(11):e013293. PubMed ID: 27899401
[TBL] [Abstract][Full Text] [Related]
5. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study.
Oberlander TF; Warburton W; Misri S; Aghajanian J; Hertzman C
Br J Psychiatry; 2008 May; 192(5):338-43. PubMed ID: 18450656
[TBL] [Abstract][Full Text] [Related]
6. Neonate characteristics after maternal use of antidepressants in late pregnancy.
Källén B
Arch Pediatr Adolesc Med; 2004 Apr; 158(4):312-6. PubMed ID: 15066868
[TBL] [Abstract][Full Text] [Related]
7. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.
Roca A; Garcia-Esteve L; Imaz ML; Torres A; Hernández S; Botet F; Gelabert E; Subirà S; Plaza A; Valdés M; Martin-Santos R
J Affect Disord; 2011 Dec; 135(1-3):208-15. PubMed ID: 21890210
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
[TBL] [Abstract][Full Text] [Related]
9. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis.
Masarwa R; Bar-Oz B; Gorelik E; Reif S; Perlman A; Matok I
Am J Obstet Gynecol; 2019 Jan; 220(1):57.e1-57.e13. PubMed ID: 30170040
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
[TBL] [Abstract][Full Text] [Related]
11. Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors.
Grzeskowiak LE; Gilbert AL; Morrison JL
J Clin Psychopharmacol; 2012 Oct; 32(5):615-21. PubMed ID: 22926594
[TBL] [Abstract][Full Text] [Related]
12. SSRI antidepressants and persistent pulmonary hypertension in newborns.
Prescrire Int; 2008 Aug; 17(96):156. PubMed ID: 19492488
[TBL] [Abstract][Full Text] [Related]
13. Neonatal complications after maternal concomitant use of SSRI and other central nervous system active drugs during the second or third trimester of pregnancy.
Källén B; Reis M
J Clin Psychopharmacol; 2012 Oct; 32(5):608-14. PubMed ID: 22926593
[TBL] [Abstract][Full Text] [Related]
14. Risks associated with selective serotonin reuptake inhibitors in pregnancy.
Malm H; Klaukka T; Neuvonen PJ
Obstet Gynecol; 2005 Dec; 106(6):1289-96. PubMed ID: 16319254
[TBL] [Abstract][Full Text] [Related]
15. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia.
Colvin L; Slack-Smith L; Stanley FJ; Bower C
CNS Drugs; 2012 Jul; 26(7):e1-14. PubMed ID: 22712699
[TBL] [Abstract][Full Text] [Related]
16. SSRI use during pregnancy and risk of stillbirth and neonatal mortality.
Jimenez-Solem E; Andersen JT; Petersen M; Broedbaek K; Lander AR; Afzal S; Torp-Pedersen C; Poulsen HE
Am J Psychiatry; 2013 Mar; 170(3):299-304. PubMed ID: 23361562
[TBL] [Abstract][Full Text] [Related]
17. The Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month.
Salisbury AL; O'Grady KE; Battle CL; Wisner KL; Anderson GM; Stroud LR; Miller-Loncar CL; Young ME; Lester BM
Am J Psychiatry; 2016 Feb; 173(2):147-57. PubMed ID: 26514656
[TBL] [Abstract][Full Text] [Related]
18. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications.
Oberlander TF; Bonaguro RJ; Misri S; Papsdorf M; Ross CJ; Simpson EM
Mol Psychiatry; 2008 Jan; 13(1):65-73. PubMed ID: 17519929
[TBL] [Abstract][Full Text] [Related]
19. Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapy.
Engelstad HJ; Roghair RD; Calarge CA; Colaizy TT; Stuart S; Haskell SE
Neonatology; 2014; 105(2):149-54. PubMed ID: 24356332
[TBL] [Abstract][Full Text] [Related]
20. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant.
Nordeng H; Spigset O
Drug Saf; 2005; 28(7):565-81. PubMed ID: 15963005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
